Secondary menu

Achievements and awards

Professor Wrochna appointed Chairman of the Scientific Policy Committee

Professor Grzegorz Wrochna
Professor Grzegorz Wrochna has been appointed Chairman of the Scientific Policy Committee, an advisory body at Polish Minister of Science and Higher Education, for six months starting June 2, 2017 ----

NCBJ will serve as another European research facility

Dyrektor NCBJ Krzysztof Kurek, Dyrektor Generalny JRC Vladimir Sucha podczas podpisywania umowy, fot JRC
NCBJ has reached an agreement on collaboration with Joint Research Centre (JRC), one of the Directorates General within the European Commission. JRC scientists carry out research to provide European Union with independent advice and support to EU science & technology policy. ----

“Nature” ranked Poland among top 10 “rising stars in science”

The Nature Index 2016 Rising Stars report published in special edition of the Nature journal has identified Poland among 10 top countries qualified as “rising stars in science”. The ranking was based on rate of increase of the WFC (weighted fractional count) index calculated for 68 prestigious journals active in natural sciences for the last 4 years. The index for Poland has risen by as much as 34% between 2012 and 2015. ----

NCBJ experts in Minister of Energy’s Advisory Committee

Members of the Minister of Energy’s Advisory Committee for High Temperature Reactors (HTR)
The Energy Minister has established an advisory committee to analyse and prepare conditions for the implementation of high-temperature nuclear reactors (HTR). The first committee meeting was held on the 20th of July and involved an official nomination for committee experts. ----

Tektrotyd, a new medicine from Poland, registered in Europe

Tektrotyd, a new medicine from Poland, registered in Europe
The 99mTc-Tektrotyd preparation developed in NCBJ POLATOM Radiopharmaceutical Centre has been just authorised as a new medicine in almost all European Union countries. Due to some unique combination of features, including low price, an effective diagnosis of some cancers has become available to a wider range of oncology patients all over the world. ----